🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

IBIO IBIO

Company Profile ↓
$1.40
+122.22% 1Y
P/E-0.80
52W High$3.07
52W Low$0.57
EPS (TTM)$-1.75

Company Overview

IBIO (IBIO) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.03.

Recent Developments

  • Jun 2025 Revenue of $400.00K (+77.8% YoY); net profit $-18.38M.
  • Trailing 12 Months Year-on-year growth — revenue +77.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR -8.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-8.54%
1 Year:77.78%

Stock Price Performance

1 Year:+122.22%
6 Months:-37.50%
3 Months:-13.04%
1 Month:-11.95%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 33% of range
$0.57 $3.07
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)42.39 · Neutral
Price Performance
1M-11.95%
3M-13.04%
6M-37.50%
1Y+122.22%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -8.5% CAGR over 5 years.
  • Trading 54.4% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.80
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-8.54%
Profit 5Y
-
Revenue (YoY)
77.78%
Earnings (YoY)
-

Profitability & Returns

ROCE
-108.92%
ROE
-123.50%
ROA
-79.26%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.06
EPS (TTM)
$-1.75

Balance Sheet & Liquidity

Debt/Equity
0.03
Quick Ratio
-
Current Ratio
11.88
Debt
$2.33M
Total Assets
$85.83M
Current Assets
$77.25M
Working Capital
$70.75M

Ownership

Promoter Holding
1.71%
Chg in Prom Hold
-
FII / Inst Holding
48.61%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$400.00K
EBITDA
-
Free Cash Flow
$-15.32M
Operating Cash Flow
$-15.30M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2013Sep 2013Dec 2013Mar 2014Sep 2014Dec 2014Mar 2015Sep 2015Dec 2015Mar 2016Sep 2016Dec 2016Mar 2017Sep 2017Dec 2017Mar 2018Sep 2018Dec 2018Mar 2019Sep 2019Dec 2019Mar 2020Sep 2020Dec 2020Mar 2021Sep 2021Dec 2021Mar 2022Sep 2022Dec 2022Mar 2023Sep 2023Dec 2023Mar 2024Sep 2024Dec 2024Mar 2025Sep 2025Dec 2025Mar 2026
Revenue ----------------------------0--50.00K--0200.00K0100.00K0-
Gross Profit ---------------------10.00K303.00K494.00K272.00K171.00K55.00K1.90M------------
Operating Income -1.86M240.00K-1.64M-1.29M-1.42M-1.67M-1.69M-1.81M-2.25M-3.07M-3.15M-3.33M-3.94M-3.36M-3.43M-3.49M-3.95M-4.01M-3.77M-3.85M-3.15M-4.06M-6.92M-7.54M-7.20M-5.22M-7.23M-6.79M-7.64M-10.57M-6.17M-5.10M-4.50M-3.63M-4.11M-4.42M-4.88M-5.95M-9.45M-8.37M
Net Income -1.76M379.00K-1.62M-1.28M-1.41M-1.65M-1.68M-1.80M-2.25M-3.04M-3.06M-3.23M-3.91M-3.83M-3.90M-3.96M-4.40M-4.47M-4.22M-4.46M-3.76M-4.68M-7.53M-8.13M-7.66M-8.94M-11.92M-12.39M-18.13M-33.55M-7.29M-5.75M-8.21M-3.17M-3.99M-4.36M-4.86M-5.72M-8.99M-7.73M
Diluted EPS -0.01---0.02--------------------0.04-3.82-1.37-1.42-2.05-68.43-11.07-4.80-4.42-0.85-0.46-0.48-0.49-0.11-0.09-0.06
R&D Expense 631.00K552.00K585.00K343.00K1.19M731.00K815.00K551.00K704.00K1.05M820.00K1.05M1.14M985.00K993.00K966.00K1.12M1.27M1.45M977.00K888.00K1.09M1.86M2.37M2.16M1.13M1.86M3.27M2.55M2.78M2.64M1.61M1.53M904.00K1.30M1.88M1.91M3.55M4.28M3.25M

Profit & Loss (Annual)

Figures in USD.

Metric Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Revenue 1.28M1.01M205.00K1.85M948.00K394.00K444.00K2.02M1.64M2.37M1.88M0225.00K400.00K
Gross Profit --------935.00K909.00K2.17M---
Operating Income -9.33M-6.67M-3.84M-6.67M-9.89M-14.27M-14.23M-15.79M-14.00M-31.11M-29.70M-29.34M-16.63M-18.60M
Net Income -5.68M-6.20M-3.67M-6.62M-9.76M-14.53M-16.11M-17.59M-16.44M-23.21M-50.30M-65.01M-24.91M-18.38M
Diluted EPS ----------3.00-5.78-106.19-6.50-1.75
R&D Expense 4.98M3.43M1.90M3.50M3.16M4.12M3.99M5.47M3.57M9.99M9.83M10.33M5.18M8.31M

Balance Sheet (Annual)

Figures in USD.

Metric Jun 2011Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Mar 2018Jun 2018Jun 2019Mar 2020Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Total Assets -9.77M9.35M6.49M12.49M51.60M36.01M-43.08M30.59M42.22M94.19M146.97M99.41M41.21M28.73M23.18M
Total Equity 196.00K6.17M5.07M6.10M11.23M9.94M8.91M4.20M16.17M2.46M3.96M56.62M108.58M63.48M15.38M21.32M14.88M
Cash & Equivalents 2.84M5.62M4.41M3.59M9.49M15.93M15.93M-4.42M4.42M-55.11M77.40M22.68M4.30M14.21M8.58M
Total Liabilities ---395.00K1.26M27.56M27.09M-26.92M28.13M-37.58M38.40M35.92M25.83M7.41M8.30M
Current Liabilities -3.60M4.29M395.00K1.26M2.29M2.01M-2.04M3.46M-5.24M6.64M30.44M22.11M3.84M6.11M

Cash Flows (Annual)

Figures in USD.

Metric Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Operating Cash Flow -6.01M-4.85M----13.16M-13.48M-13.97M-13.35M-30.06M-37.48M-30.44M-18.55M-15.30M
Investing Cash Flow -245.00K-195.00K----1.59M-1.08M-990.00K-1.15M-26.48M-5.13M7.01M906.00K742.00K
Financing Cash Flow 9.04M3.83M----170.00K22.41M3.45M65.19M78.83M-6.12M2.30M24.49M8.93M
Capital Expenditure -1.00K-7.00K-4.00K-13.00K-68.00K-1.32M-934.00K-920.00K-1.08M-4.92M-7.33M-5.74M-210.00K-16.00K
Free Cash Flow -6.01M-4.86M----14.49M-14.41M-14.89M-14.42M-34.98M-44.81M-36.17M-18.76M-15.32M

Ratios (Annual)

Figures in %.

Metric Jun 2012Jun 2013Jun 2014Jun 2015Jun 2016Jun 2017Jun 2018Jun 2019Jun 2020Jun 2021Jun 2022Jun 2023Jun 2024Jun 2025
Gross Margin % --------57.1%38.3%115.0%---
Operating Margin % -730.4%-662.1%-1,873.2%-360.1%-1,043.6%-3,622.8%-3,204.3%-782.4%-854.9%-1,312.1%-1,576.3%--7,392.9%-4,650.5%
Net Margin % -444.5%-615.5%-1,788.3%-357.9%-1,030.0%-3,688.3%-3,627.3%-871.8%-1,003.6%-978.8%-2,670.0%--11,069.8%-4,594.2%
ROE % -92.0%-122.3%-60.1%-59.0%-98.3%-163.0%-99.6%-714.3%-29.0%-21.4%-79.2%-422.7%-116.8%-123.5%
ROCE % -151.2%-131.6%-63.0%-59.4%-20.1%-42.0%-34.7%-58.2%-15.7%-22.2%-43.1%-153.6%-66.8%-108.9%

Shareholding Pattern

Insiders
1.71%
Institutions
48.61%
Public Float
49.46%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IBIO

Google News ue, 04 Aug 2026

iBio (IBIO) awards 430,000 stock options to its Chief Medical Officer - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOb0JHZS1uVkdaaHBiTDc4VkRXYnh6a19xay1BQnR4OWFQeWNSWHptc1lxLWdxZEFTQjNnZ2xzX1luRV9JWFNJSmVRMTk1eUFPQzZWV0wxWTlGa2VoS2hjdFh2aXFpTVN1cjctLVdEeEMwQTBOSzRVU0s3SFdCT2gxcmw2dUcxbUp6SXZZWk…

Google News ue, 04 Aug 2026

iBio Names Dr. Molly Carr as Chief Medical Officer to Advance Clinical-Stage Pipeline - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNREJ1RWFFcFF1TmYyNG0yYU9GdW5zMnowQU1fZzV6YTB2VkpRQnVPd0lkcC15M0JNNGFFM3VkWmtvLWFrTDdUbFdnaDM0U0JNeE0tRHRiX2QyNE5PRXNJYWVVQ0NBenZaeTNhZTlXYXJwWmhyRXBNZURfY0t1STd0eFZNbTBTSF8ybkN5a1…

Google News hu, 11 Jun 2026

Could iBio (IBIO) Be an Underrated Obesity Stock? - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOTlFIb0FYR3hNRmkzY21UQVVuUTlfMV9zbGZ6UUFnLVFwZzU2NjB3NC1MQk85aU1CLU1yWmFjRXNXdVUyUEFtcVNjSGIybTNhVHQybHRnOFpfNTE0Q3lHTmZxTDR5NWRISWVtX1Z1NXhQakJGaklkRU92WTNES0pBUnZ0SG5IZzk4NVRhSz…

Google News hu, 05 Mar 2026

IBIO Stock Soars 12% Pre-Market After Company Announces $26 Million Private Placement - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNUU0wS0NTdnRsdUE1UTJlMEYtN3J1RHpITHNaUFFxenVWaGdMNU9WVGNlWkFmWFIwcUlKN2wxQ3V4SGE4RDQtZVNRYVhxZWQ5ZTVtY0dmSEowb0FTZTBOaUtlSVRiZU9NODh5WjFyTFFjalFISm5qbFBTcmRYcDV5SzlkOHFjUmFseHM3d2…

Google News hu, 28 May 2026

IBIO - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9zemJuTVBDcWhQeXpuQ1lCWEU3WlU0TkQ4RVEyaHVDNnUxdTVFV19JZXBIZzNYOTdxMW14b3dYRnEzTngyYWc?oc=5" target="_blank">IBIO</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News hu, 25 Jun 2026

IBIO Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1hNU0yVURBcHVadzJhUWNrYTU3Y2tEUFM4R3p0a3ZobEdjVlRYZmw3elkwNzJMUno5WHM1RjZiZmNUdzJpd2R6ek1pdWUwR0VNbExxZnl1Z29FeFozMS1kcVNkOVh6cDZBaGtsMzYyc3dkTHd6bWZ2dFFn?oc=5" target="_blank">IBI…

IBIO — Frequently Asked Questions

What is the current share price of IBIO?

As of 2026-08-05 17:25 PDT, IBIO trades at $1.40 on NASDAQ/NYSE. Its 52-week range is $0.57 to $3.07.

What is the P/E ratio of IBIO?

IBIO trades at a trailing price-to-earnings (P/E) ratio of -0.80.

What is the return on equity (ROE) of IBIO?

IBIO has a return on equity (ROE) of -123.50%. Its return on capital employed (ROCE) is -108.92%.

Is IBIO a good stock to buy?

This page provides a data-driven analysis of IBIO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space